Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anika Therapeutics (ANIK) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for Anika Therapeutics (ANIK) over the last 15 years, with Q3 2025 value amounting to 0.07%.

  • Anika Therapeutics' Return on Capital Employed fell 1600.0% to 0.07% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.07%, marking a year-over-year decrease of 1600.0%. This contributed to the annual value of 0.02% for FY2024, which is 300.0% down from last year.
  • According to the latest figures from Q3 2025, Anika Therapeutics' Return on Capital Employed is 0.07%, which was down 1600.0% from 0.05% recorded in Q2 2025.
  • Anika Therapeutics' Return on Capital Employed's 5-year high stood at 0.09% during Q3 2024, with a 5-year trough of 0.11% in Q1 2021.
  • Its 5-year average for Return on Capital Employed is 0.02%, with a median of 0.02% in 2021.
  • Per our database at Business Quant, Anika Therapeutics' Return on Capital Employed crashed by -2100bps in 2021 and then soared by 1200bps in 2024.
  • Quarter analysis of 5 years shows Anika Therapeutics' Return on Capital Employed stood at 0.01% in 2021, then surged by 40bps to 0.01% in 2022, then tumbled by -73bps to 0.0% in 2023, then crashed by -937bps to 0.03% in 2024, then plummeted by -178bps to 0.07% in 2025.
  • Its Return on Capital Employed was 0.07% in Q3 2025, compared to 0.05% in Q2 2025 and 0.04% in Q1 2025.